- Home
- U S Membranous Nephropathy Market
U.S. Membranous Nephropathy Market - Industry Trends and Forecast to 2028
- Published Date: September, 2022 | Report ID: CLS-277 | No of pages: 136 | Format:
The U.S. membranous nephropathy market is projected to register a CAGR of 5.0% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028.
Market Segmentation:
U.S. Membranous Nephropathy Market, By Disease Type (Primary Membranous Nephropathy, Secondary Membranous Nephropathy), Type (Diagnosis, Treatment), Cause (Autoimmune Disease, Hepatitis B and C, Cancer, NSAID Medications, Others), Population Type (Children, Adults), End User (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) Industry Trends and Forecast to 2028
Some of the major factors contributing to the growth of the U.S. membranous nephropathy market are:
Increase in kidney disorders
Ongoing research regarding membranous nephropathy
Market Players:
The key market players for the U.S. membranous nephropathy market are listed below:
Solco Healthcare
ALMATICA PHARMA LLC
Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila)
Novartis AG
Pfizer Inc.
Viatris Inc.
Avet Pharmaceuticals Inc.
Teva Pharmaceutical USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.),
Lupin Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.)
Hikma Pharmaceuticals PLC
Accord Healthcare
Sun Pharmaceutical Industries Ltd.
CareDx, Inc.
Genentech, Inc. (a subsidiary of F. Hoffmann-La Roche Ltd)
Azurity Pharmaceuticals, Inc.
Fresenius Kabi USA (a subsidiary of Fresenius SE & Co. KGaA)
Strides Pharma Science Limited
Alembic Pharmaceuticals Limited
AbbVie Inc.
TABLE OF CONTENT
TABLE OF CONTENTS 1 INTRODUCTION 12 1.1 OBJECTIVES OF THE STUDY 12 1.2 MARKET DEFINITION 12 1.3 OVERVIEW OF U.S. MEMBRANOUS NEPHROPATHY MARKET 12 1.4 LIMITATIONS 14 1.5 MARKETS COVERED 15 2 MARKET SEGMENTATION 17 2.1 MARKETS COVERED 17 2.2 GEOGRAPHICAL SCOPE 18 2.3 YEARS CONSIDERED FOR THE STUDY 18 2.4 CURRENCY AND PRICING 18 2.5 DBMR TRIPOD DATA VALIDATION MODEL 19 2.6 MULTIVARIATE MODELLING 22 2.7 DIASEASE TYPE LIFELINE CURVE 22 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 23 2.9 DBMR MARKET POSITION GRID 24 2.10 VENDOR SHARE ANALYSIS 25 2.11 MARKET TYPE COVERAGE GRID 26 2.12 SECONDARY SOURCES 27 2.13 ASSUMPTIONS 27 3 EXECUTIVE SUMMARY 28 4 PIPELINE ANALYSIS 32 5 U.S. MEMBRANOUS NEPHROPATHY MARKET: LAWS AND REGULATIONS 33 6 MARKET OVERVIEW 36 6.1 DRIVERS 38 6.1.1 INCREASE IN KIDNEY DISORDERS 38 6.1.2 ONGOING RESEARCH REGARDING MEMBRANOUS NEPHROPATHY 38 6.1.3 INCREASE IN GERIATRIC POPULATION 39 6.1.4 INCREASE IN SMOKING AND ALCOHOL CONSUMPTION POPULATION 40 6.1.5 HIGH PREVALENCE OF INFECTIOUS DISEASES 40 6.2 RESTRAINTS 41 6.2.1 COMPLICATIONS RELATED TO KIDNEY TRANSPLANTATION 41 6.2.2 UNAVILABILITY OF SPECIFIC TREATMENTS FOR MEMBRANOUS NEPHROPATHY 42 6.2.3 COMPLICATIONS RELATED TO DRUGS PRESCRIBED IN MEMBRANOUS NEPHROPATHY 42 6.3 OPPORTUNITIES 43 6.3.1 INCREASING HEALTHCARE EXPENDITURE 43 6.3.2 INCREASE IN GENRIC DRUGS MANUFACTURING COMPANIES 44 6.3.3 INCREASING DISPOSABLE INCOME 45 6.3.4 INCREASE IN AGREEMENT AND ACQUISITION BY MARKET PLAYERS 46 6.4 CHALLENGES 47 6.4.1 PRODUCT RECALLS 47 6.4.2 LACK OF SKILLED PROFESSIONALS 48 6.4.3 UNCERTAINITY IN BENEFITS FOR AVAILABLE THERAPIES 48 7 COVID-19 IMPACT ON THE U.S. MEMBRANOUS NEPHROPATHY MARKET 49 7.1 PRICE IMPACT 49 7.2 IMPACT ON DEMAND 49 7.3 IMPACT ON SUPPLY CHAIN 50 7.4 STRATEGIC DECISIONS FOR MANUFACTURERS 50 7.5 CONCLUSION 51 8 U.S. MEMBRANOUS NEPHROPATHY MARKET, BY DISEASE TYPE 52 8.1 OVERVIEW 53 8.2 PRIMARY MEMBRANOUS NEPHROPATHY 56 8.3 SECONDARY MEMBRANOUS NEPHROPATHY 56 9 U.S. MEMBRANOUS NEPHROPATHYMARKET, BY TYPE 57 9.1 OVERVIEW 58 9.2 DIAGNOSIS 61 9.2.1 LABORATORY TEST 61 9.2.2 URINALYSIS 62 9.2.2.1 Blood test 62 9.2.2.2 Glomerular filtration rate (GFR) 62 9.2.2.3 Creatinine test 62 9.2.2.4 Lipid panel 62 9.2.2.5 Others 62 9.2.3 IMAGING TEST 62 9.2.4 KIDNEY BIOPSY 62 9.3 TREATMENT 62 9.3.1 ACE-INHIBITOR 63 9.3.1.1 Lisinopril 63 9.3.1.2 Enalapril 63 9.3.1.3 Ramipril 63 9.3.1.4 Benazepril 64 9.3.1.5 Others 64 9.3.2 ANGIOTENSIN II RECEPTOR BLOCKERS 64 9.3.2.1 Losartan 64 9.3.2.2 Valsatan 64 9.3.2.3 Irbesartan 64 9.3.2.4 Others 64 9.3.3 IMMUNOSUPPRESSIVE THERAPY 65 9.3.3.1 Cyclophosphamide 65 9.3.3.2 Cyclosporine 65 9.3.3.3 Rituximab 65 9.3.3.4 Corticosteroids 65 9.3.3.5 IV immune globulin 65 9.3.3.6 Others 65 9.3.4 DIURETICS 66 9.3.4.1 Furosemide 66 9.3.4.2 Torsemide 66 9.3.4.3 Bumetanide 66 9.3.4.4 Others 66 10 U.S. MEMBRANOUS NEPHROPATHYMARKET, BY CAUSE 67 10.1 OVERVIEW 68 10.2 AUTOIMMUNE DISEASE 71 10.3 HEPATITIS B AND C 71 10.4 NASID MEDICATIONS 71 10.5 CANCER 72 10.6 OTHERS 72 11 U.S. MEMBRANOUS NEPHROPATHY MARKET, BY POPULATION TYPE 73 11.1 OVERVIEW 74 11.2 ADULTS 77 11.3 CHILDREN 77 12 U.S. MEMBRANOUS NEPHROPATHYMARKET, BY END USER 78 12.1 OVERVIEW 79 12.2 HOSPITALS 82 12.3 SPECIALTY CLINICS 82 12.4 HOME HEALTHCARE 82 12.5 OTHERS 83 13 U.S. MEMBRANOUS NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL 84 13.1 OVERVIEW 85 13.2 HOSPITAL PHARMACY 87 13.3 RETAIL PHARMACY 88 13.4 ONLINE PHARMACY 88 13.5 DIRECT TENDER 88 13.6 OTHERS 89 14 THE U.S. MEMBRANOUS NEPHROPATHY MARKET, COMPANY LANDSCAPE 90 14.1 COMPANY SHARE ANALYSIS: GLOBAL 90 15 SWOT 91 16 COMPANY PROFILES 92 16.1 TEVA PHARMACEUTICALS, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.) 92 16.1.1 COMPANY SNAPSHOT 92 16.1.2 RECENT FINANCIALS 92 16.1.3 PRODUCT PORTFOLIO 93 16.1.4 RECENT DEVELOPMENTS 93 16.2 PFIZER, INC. 95 16.2.1 COMPANY SNAPSHOT 95 16.2.2 RECENT FINANCIALS 95 16.2.3 PRODUCT PORTFOLIO 96 16.2.4 RECENT DEVELOPMENTS 96 16.3 NOVARTIS AG 97 16.3.1 COMPANY SNAPSHOT 97 16.3.2 REVENUE FINANCIALS 97 16.3.3 PRODUCT PORTFOLIO 98 16.3.4 RECENT DEVELOPMENTS 98 16.4 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA) 99 16.4.1 COMPANY SNAPSHOT 99 16.4.2 RECENT FINANCIALS 99 16.4.3 PRODUCT PORTFOLIO 100 16.4.4 RECENT DEVELOPMENTS 100 16.5 LUPIN PHARMACEUTICALS, INC. 101 16.5.1 COMPANY SNAPSHOT 101 16.5.2 PRODUCT PORTFOLIO 101 16.5.3 RECENT DEVELOPMENTS 101 16.6 HIKMA PHARMACEUTICALS PLC 103 16.6.1 COMPANY SNAPSHOT 103 16.6.2 REVENUE ANALYSIS 103 16.6.3 PRODUCT PORTFOLIO 104 16.6.4 RECENT DEVELOPMENTS 104 16.7 GENENTECH, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD) 105 16.7.1 COMPANY SNAPSHOT 105 16.7.2 REVENUE ANALYSIS 105 16.7.3 PRODUCT PORTFOLIO 106 16.7.4 RECENT DEVELOPMENTS 106 16.8 MERCK SHARP & DOHME CORP., (A SUBSIDIARY OF MERCK & CO., INC.) 107 16.8.1 COMPANY SNAPSHOT 107 16.8.2 REVENUE ANALYSIS 107 16.8.3 PRODUCT PORTFOLIO 108 16.8.4 RECENT DEVELOPMENTS 108 16.9 ALEMBIC PHARMACEUTICALS LIMITED 109 16.9.1 COMPANY SNAPSHOT 109 16.9.2 REVENUE ANALYSIS 110 16.9.3 PRODUCT PORTFOLIO 110 16.9.4 RECENT DEVELOPMENTS 110 16.10 FRESENIUS KABI USA (A SUBSIDIARY OF FRESENIUS SE & CO. KGAA) 112 16.10.1 COMPANY SNAPSHOT 112 16.10.2 REVENUE ANALYSIS 112 16.10.3 PRODUCT PORTFOLIO 112 16.10.4 RECENT DEVELOPMENTS 113 16.11 ABBVIE INC. 114 16.11.1 COMPANY SNAPSHOT 114 16.11.2 REVENUE ANALYSIS 114 16.11.3 PRODUCT PORTFOLIO 115 16.11.4 RECENT DEVELOPMENTS 115 16.12 ACCORD HEALTHCARE 116 16.12.1 COMPANY SNAPSHOT 116 16.12.2 PRODUCT PORTFOLIO 116 16.12.3 RECENT DEVELOPMENTS 117 16.13 ALMATICA PHARMA LLC 118 16.13.1 COMPANY SNAPSHOT 118 16.13.2 PRODUCT PORTFOLIO 118 16.13.3 RECENT DEVELOPMENTS 118 16.14 AVET PHARMACEUTICALS, INC. 119 16.14.1 COMPANY SNAPSHOT 119 16.14.2 PRODUCT PORTFOLIO 119 16.14.3 RECENT DEVELOPMENTS 119 16.15 AZURITY PHARMACEUTICALS, INC. 121 16.15.1 COMPANY SNAPSHOT 121 16.15.2 PRODUCT PORTFOLIO 121 16.15.3 RECENT DEVELOPMENT 121 16.16 CAREDX, INC 122 16.16.1 COMPANY SNAPSHOT 122 16.16.2 REVENUE ANALYSIS 122 16.16.3 PRODUCT PORTFOLIO 123 16.16.4 RECENT DEVELOPMENTS 123 16.17 SOLCO HEALTHCARE 125 16.17.1 COMPANY SNAPSHOT 125 16.17.2 PRODUCT PORTFOLIO 125 16.17.3 RECENT DEVELOPMENTS 126 16.18 STRIDES PHARMA SCIENCE LIMITED 127 16.18.1 COMPANY SNAPSHOT 127 16.18.2 REVENUE ANALYSIS 127 16.18.3 PRODUCT PORTFOLIO 128 16.18.4 RECENT DEVELOPMENTS 128 16.19 SUN PHARMACEUTICAL INDUSTRIES LTD. 129 16.19.1 COMPANY SNAPSHOT 129 16.19.2 REVENUE ANALYSIS 129 16.19.3 PRODUCT PORTFOLIO 130 16.19.4 RECENT DEVELOPMENTS 130 16.20 VIATRIS INC. 131 16.20.1 COMPANY SNAPSHOT 131 16.20.2 PRODUCT PORTFOLIO 131 16.20.3 RECENT DEVELOPMENTS 131 17 QUESTIONNAIRE 133 18 RELATED REPORTS 136Segmentation
Short Description U.S. Membranous Nephropathy Market, By Disease Type (Primary Membranous Nephropathy, Secondary Membranous Nephropathy), Type (Diagnosis, Treatment), Cause (Autoimmune Disease, Hepatitis B and C, Cancer, NSAID Medications, Others), Population Type (Children, Adults), End User (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) Industry Trends and Forecast to 2028 Market Definition: Membranous nephropathy is a kind of kidney disorder in which the small blood vessels of the kidney known as glomeruli whose function is to filter the waste from the blood which gets thick and damaged. The condition leads to the excretion of excess protein in the urine which is known as proteinuria. It is a type of glomerular disease and autoimmune disease and membranous nephropathy is considered as one of the causes of nephrotic syndrome. Market Segmentation: The membranous nephropathy market is segmented on the basis of disease type, type, cause, population type, end user and distribution channel. On the basis of disease type, the membranous nephropathy market is segmented into primary membranous nephropathy and secondary membranous nephropathy On the basis of type, the membranous nephropathy market is segmented into diagnosis and treatment On the basis of cause, the membranous nephropathy market is segmented into autoimmune disease, hepatitis B and C, cancer, NSAID medications and others On the basis of population type, the membranous nephropathy market is segmented into children and adults On the basis of end user, the membranous nephropathy market is segmented into hospitals, specialty clinics, home healthcare and others On the basis of distribution channel, the membranous nephropathy market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others Market Players The key market players for the U.S. membranous nephropathy market are listed below: Solco Healthcare ALMATICA PHARMA LLC Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila) Novartis AG Pfizer Inc. Viatris Inc. Avet Pharmaceuticals Inc. Teva Pharmaceutical USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.), Lupin Pharmaceuticals, Inc. Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.) Hikma Pharmaceuticals PLC Accord Healthcare Sun Pharmaceutical Industries Ltd. CareDx, Inc. Genentech, Inc. (a subsidiary of F. Hoffmann-La Roche Ltd) Azurity Pharmaceuticals, Inc. Fresenius Kabi USA (a subsidiary of Fresenius SE & Co. KGaA) Strides Pharma Science Limited Alembic Pharmaceuticals Limited AbbVie Inc.Methodology
Why Choose Us
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.